Histone deacetylase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
== Relevance ==
== Relevance ==
-
HDAC inhibitors are used in cancer therapy<ref>PMID:11902574</ref>. Sirtuins play a role in cancer, metabolic activity and neurodegenerative diseases<ref>PMID:17456799</ref>.
+
HDAC inhibitors are used in cancer therapy<ref>PMID:11902574</ref>. Sirtuins play a role in cancer, metabolic activity and neurodegenerative diseases<ref>PMID:17456799</ref>. HDAC inhibitor SAHA or Vorinostat is used in the treatment of cutaneous T cell lymphoma<ref>PMID:17962618</ref>.
== 3D Structures of histone deacetylase ==
== 3D Structures of histone deacetylase ==

Revision as of 11:39, 23 March 2016

Template:STRUCTURE 3ewf

Contents

Function

Histone deacetylase (HDAC) catalyzes the removal of acetyl group from ε-N-acetyl lysine in histones[1]. HDAC contains Zn. DNA expression is regulated by acetylation and de-acetylation. SAHA is a common inhibitor of HDAC. HDAC are classified according to their domain organization into 4 classes.

  • HDAC class I are homologous to yeast Rpd3.
  • HDAC class II are homologous to yeast HdaI.
  • HDAC class III called sirtuin - (Silent Information Regulator) (SIRT) are NAD-dependent HDAC [2].

For additional details see

Relevance

HDAC inhibitors are used in cancer therapy[3]. Sirtuins play a role in cancer, metabolic activity and neurodegenerative diseases[4]. HDAC inhibitor SAHA or Vorinostat is used in the treatment of cutaneous T cell lymphoma[5].

3D Structures of histone deacetylase

Updated on 23-March-2016


References

  1. ↑ Joshi P, Greco TM, Guise AJ, Luo Y, Yu F, Nesvizhskii AI, Cristea IM. The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol. 2013;9:672. doi: 10.1038/msb.2013.26. PMID:23752268 doi:http://dx.doi.org/10.1038/msb.2013.26
  2. ↑ Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008 Feb;7(2):104-12. doi: 10.1016/j.cmet.2007.11.006. PMID:18249170 doi:http://dx.doi.org/10.1016/j.cmet.2007.11.006
  3. ↑ Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001 Dec;1(3):194-202. PMID:11902574 doi:http://dx.doi.org/10.1038/35106079
  4. ↑ Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol. 2007 Aug;21(8):1745-55. Epub 2007 Apr 24. PMID:17456799 doi:http://dx.doi.org/10.1210/me.2007-0079
  5. ↑ Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007 Oct;12(10):1247-52. PMID:17962618 doi:http://dx.doi.org/10.1634/theoncologist.12-10-1247

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Histone_deacetylase"
Personal tools